Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gammon

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Journal of Infectious Diseases|July 1, 1990
A human monoclonal antibody that protects mice against Pseudomonas-induced pneumoniaH J Zweerink, L J Detolla, M C Gammon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1991
The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2M A Bednarek, S Y Sauma, M C Gammon, et al.
Journal of Immunological Methods|May 17, 1991
Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytesM A Bednarek, S A Engl, M C Gammon, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 19, 2009
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosisDavid C Gammon, Traci Dutton, Bilal Piperdi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1992
Endogenous loading of HLA-A2 molecules with an analog of the influenza virus matrix protein-derived peptide and its inhibition by an exogenous peptide antagonistM C Gammon, M A Bednarek, W E Biddison, et al.
Infection and Immunity|May 1, 1988
X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosaH J Zweerink, M C Gammon, C F Hutchison, et al.
Infection and Immunity|August 1, 1988
Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosaH J Zweerink, M C Gammon, C F Hutchison, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1993
Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cellsH J Zweerink, M C Gammon, U Utz, et al.
Human Immunology|August 1, 1993
Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix proteinS Y Sauma, M C Gammon, M A Bednarek, et al.
Human Immunology|April 1, 1994
Mutation of the alpha 2 domain disulfide bridge of the class I molecule HLA-A*0201. Effect on maturation and peptide presentationR J Warburton, M Matsui, S L Rowland-Jones, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Infectious Diseases|July 1, 1990
A human monoclonal antibody that protects mice against Pseudomonas-induced pneumoniaH J Zweerink, L J Detolla, M C Gammon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1991
The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2M A Bednarek, S Y Sauma, M C Gammon, et al.
Journal of Immunological Methods|May 17, 1991
Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytesM A Bednarek, S A Engl, M C Gammon, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 19, 2009
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosisDavid C Gammon, Traci Dutton, Bilal Piperdi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1992
Endogenous loading of HLA-A2 molecules with an analog of the influenza virus matrix protein-derived peptide and its inhibition by an exogenous peptide antagonistM C Gammon, M A Bednarek, W E Biddison, et al.
Infection and Immunity|May 1, 1988
X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosaH J Zweerink, M C Gammon, C F Hutchison, et al.
Infection and Immunity|August 1, 1988
Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosaH J Zweerink, M C Gammon, C F Hutchison, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1993
Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cellsH J Zweerink, M C Gammon, U Utz, et al.
Human Immunology|August 1, 1993
Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix proteinS Y Sauma, M C Gammon, M A Bednarek, et al.
Human Immunology|April 1, 1994
Mutation of the alpha 2 domain disulfide bridge of the class I molecule HLA-A*0201. Effect on maturation and peptide presentationR J Warburton, M Matsui, S L Rowland-Jones, et al.
Pageof 2